Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) announced upbeat results from a Phase III clinical trial of its fibromyalgia treatment sodium oxybate sending the stock price soaring $1.29 to $4.54.
Jazz Pharmaceuticals Reports Positive Trial Results
June 25, 2009 at 13:30 PM EDT
